A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
- Status
- TERMINATED
- Phase
- PHASE3
Clinical Trials Related to Incyte Corporation
Related studies linked through entity extraction aliases.
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
- Status
- TERMINATED
- Phase
- PHASE2
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
- Status
- RECRUITING
- Phase
- PHASE2
A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris
- Status
- WITHDRAWN
- Phase
- PHASE2
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE1
TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
- Status
- COMPLETED
- Phase
- PHASE3
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis
- Status
- COMPLETED
- Phase
- PHASE3
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
- Status
- COMPLETED
- Phase
- PHASE2
Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
- Status
- TERMINATED
- Phase
- PHASE3